Rhabdomyosarcoma natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
| Line 27: | Line 27: | ||
** Secondary malignancies | ** Secondary malignancies | ||
*** Skin and bone tumors regarding radiotherapy | *** Skin and bone tumors regarding radiotherapy | ||
* Long-term complications after treatment | * Long-term complications after treatment regarding to different organs are listed below: | ||
{| class="wikitable" | |||
|+ | |||
!Affected organs | |||
!Long-term complications | |||
|- | |||
|Head and neck <ref name="pmid10491544">{{cite journal| author=Raney RB, Asmar L, Vassilopoulou-Sellin R, Klein MJ, Donaldson SS, Green J et al.| title=Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: A descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and - III. IRS Group of the Children's Cancer Group and the Pediatric Oncology Group. | journal=Med Pediatr Oncol | year= 1999 | volume= 33 | issue= 4 | pages= 362-71 | pmid=10491544 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10491544 }}</ref> | |||
| | |||
* Short stature and facial asymmetry | |||
* Poor dentition | |||
* Impaired hearing, vision, and learning | |||
|- | |||
|Bladder and bowl <ref name="pmid8453560">{{cite journal| author=Raney B, Heyn R, Hays DM, Tefft M, Newton WA, Wharam M et al.| title=Sequelae of treatment in 109 patients followed for 5 to 15 years after diagnosis of sarcoma of the bladder and prostate. A report from the Intergroup Rhabdomyosarcoma Study Committee. | journal=Cancer | year= 1993 | volume= 71 | issue= 7 | pages= 2387-94 | pmid=8453560 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8453560 }}</ref> | |||
|Bladder: | |||
* Incontinency, | |||
* Frequency | |||
* Nocturia | |||
Bowl: | |||
* Hemorrhagic cystitis | |||
* Primary hypogonadism | |||
|- | |||
| | |||
| | |||
|} | |||
==Prognosis== | ==Prognosis== | ||
Revision as of 16:36, 20 February 2019
|
Rhabdomyosarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Rhabdomyosarcoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Rhabdomyosarcoma natural history, complications and prognosis |
|
FDA on Rhabdomyosarcoma natural history, complications and prognosis |
|
CDC on Rhabdomyosarcoma natural history, complications and prognosis |
|
Rhabdomyosarcoma natural history, complications and prognosis in the news |
|
Blogs on Rhabdomyosarcoma natural history, complications and prognosis |
|
Risk calculators and risk factors for Rhabdomyosarcoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Shadan Mehraban, M.D.[2]
Overview
Common complications of rhabdomyosarcoma include metastasis to lung, bone marrow, and bone. Rhabdomyosarcoma is associated with a 5 year survival rate of 72%. The presence of metastasis is associated with a particularly poor prognosis. Histologically, the embryonal type rhabdomyosarcoma and anatomically, the orbital and genitourinary tract rhabdomyosarcomas have the most favorable prognosis.
Complications
- Rhabdomyosarcoma may cause metastasis to other organs.[1]
- Patients may develop with some complications after treatment such as:[5]
- Cardiomyopathy
- Regarding anthracycline and cyclophosphamide use
- Pulmonary failure
- Renal electrolyte wasting
- Regarding ifosfamide use
- Acute myelogenous leukemia
- Regarding etoposide use
- Secondary malignancies
- Skin and bone tumors regarding radiotherapy
- Cardiomyopathy
- Long-term complications after treatment regarding to different organs are listed below:
| Affected organs | Long-term complications |
|---|---|
| Head and neck [6] |
|
| Bladder and bowl [7] | Bladder:
Bowl:
|
Prognosis
- Rhabdomyosarcoma is associated with a 5 year survival rate of 72%.
- The presence of metastasis is associated with a particularly poor prognosis among patients with rhabdomyosarcoma. The 5 year event free survival rate is less than 30%.
- Histologically, the embryonal type rhabdomyosarcoma and anatomically, the orbital and genitourinary tract rhabdomyosarcomas have the most favorable prognosis.
References
- ↑ Raney RB, Tefft M, Maurer HM, Ragab AH, Hays DM, Soule EH; et al. (1988). "Disease patterns and survival rate in children with metastatic soft-tissue sarcoma. A report from the Intergroup Rhabdomyosarcoma Study (IRS)-I". Cancer. 62 (7): 1257–66. PMID 2843274.
- ↑ Koscielniak E, Rodary C, Flamant F, Carli M, Treuner J, Pinkerton CR; et al. (1992). "Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: a retrospective European multi-center analysis". Med Pediatr Oncol. 20 (3): 209–14. PMID 1574030.
- ↑ Ruymann FB, Newton WA, Ragab AH, Donaldson MH, Foulkes M (1984). "Bone marrow metastases at diagnosis in children and adolescents with rhabdomyosarcoma. A report from the intergroup rhabdomyosarcoma study". Cancer. 53 (2): 368–73. PMID 6546301.
- ↑ Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM; et al. (2003). "Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV". J Clin Oncol. 21 (1): 78–84. doi:10.1200/JCO.2003.06.129. PMID 12506174.
- ↑ Punyko JA, Mertens AC, Gurney JG, Yasui Y, Donaldson SS, Rodeberg DA; et al. (2005). "Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the childhood cancer survivor study". Pediatr Blood Cancer. 44 (7): 643–53. doi:10.1002/pbc.20310. PMID 15700252.
- ↑ Raney RB, Asmar L, Vassilopoulou-Sellin R, Klein MJ, Donaldson SS, Green J; et al. (1999). "Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: A descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and - III. IRS Group of the Children's Cancer Group and the Pediatric Oncology Group". Med Pediatr Oncol. 33 (4): 362–71. PMID 10491544.
- ↑ Raney B, Heyn R, Hays DM, Tefft M, Newton WA, Wharam M; et al. (1993). "Sequelae of treatment in 109 patients followed for 5 to 15 years after diagnosis of sarcoma of the bladder and prostate. A report from the Intergroup Rhabdomyosarcoma Study Committee". Cancer. 71 (7): 2387–94. PMID 8453560.